

L1 FILE 'REGISTRY' ENTERED AT 10:46:14 ON 05 APR 2004
L2 292 S [LT][GEN][RK]L[AST][QN]EL.[RK]LQTYPRTN[TV]GS[NG]T[PY]/SQSP
82 S L1 AND 25-30/SQ L

L3 FILE 'CAPLUS' ENTERED AT 10:50:23 ON 05 APR 2004
37 S L2

L4 FILE 'REGISTRY' ENTERED AT 10:54:03 ON 05 APR 2004
2 S LSTCVLGRLSQELHRLQTYPRNTGSENTY/SQEP

L5 FILE 'CAPLUS' ENTERED AT 10:55:02 ON 05 APR 2004
1 S L4
S (238740-08-4/REG# OR 238740-09-5/REG# OR 238740-10-8/REG#

L6 FILE 'REGISTRY' ENTERED AT 10:58:42 ON 05 APR 2004
1 S 238740-22-2/RN

L7 FILE 'CAPLUS' ENTERED AT 10:58:43 ON 05 APR 2004
1 S L6

L8 FILE 'REGISTRY' ENTERED AT 10:58:43 ON 05 APR 2004
1 S 238740-21-1/RN

L9 FILE 'CAPLUS' ENTERED AT 10:58:43 ON 05 APR 2004
1 S L8

L10 FILE 'REGISTRY' ENTERED AT 10:58:44 ON 05 APR 2004
1 S 238740-20-0/RN

L11 FILE 'CAPLUS' ENTERED AT 10:58:44 ON 05 APR 2004
1 S L10

L12 FILE 'REGISTRY' ENTERED AT 10:58:44 ON 05 APR 2004
1 S 238740-19-7/RN

L13 FILE 'CAPLUS' ENTERED AT 10:58:45 ON 05 APR 2004
1 S L12

L14 FILE 'REGISTRY' ENTERED AT 10:58:45 ON 05 APR 2004
1 S 238740-18-6/RN

L15 FILE 'CAPLUS' ENTERED AT 10:58:45 ON 05 APR 2004
1 S L14

L16 FILE 'REGISTRY' ENTERED AT 10:58:46 ON 05 APR 2004
1 S 238740-17-5/RN

L17 FILE 'CAPLUS' ENTERED AT 10:58:46 ON 05 APR 2004
1 S L16

L18 FILE 'REGISTRY' ENTERED AT 10:58:47 ON 05 APR 2004
1 S 238740-16-4/RN

L19 FILE 'CAPLUS' ENTERED AT 10:58:47 ON 05 APR 2004
1 S L18

L20 FILE 'REGISTRY' ENTERED AT 10:58:47 ON 05 APR 2004
1 S 238740-15-3/RN

L21 FILE 'CAPLUS' ENTERED AT 10:58:48 ON 05 APR 2004
1 S L20

L22 FILE 'REGISTRY' ENTERED AT 10:58:48 ON 05 APR 2004
1 S 238740-14-2/RN

L23 FILE 'CAPLUS' ENTERED AT 10:58:48 ON 05 APR 2004
1 S L22

L24 FILE 'REGISTRY' ENTERED AT 10:58:49 ON 05 APR 2004
1 S 238740-13-1/RN

L25 FILE 'CAPLUS' ENTERED AT 10:58:49 ON 05 APR 2004
1 S L24

L26 FILE 'REGISTRY' ENTERED AT 10:58:50 ON 05 APR 2004
1 S 238740-12-0/RN

L27 FILE 'CAPLUS' ENTERED AT 10:58:50 ON 05 APR 2004
1 S L26

L28 FILE 'REGISTRY' ENTERED AT 10:58:51 ON 05 APR 2004
1 S 238740-10-8/RN

L29 FILE 'CAPLUS' ENTERED AT 10:58:51 ON 05 APR 2004
1 S L28

L30 FILE 'REGISTRY' ENTERED AT 10:58:51 ON 05 APR 2004
1 S 238740-09-5/RN

L31 FILE 'CAPLUS' ENTERED AT 10:58:51 ON 05 APR 2004
1 S L30

L32 FILE 'REGISTRY' ENTERED AT 10:58:52 ON 05 APR 2004
1 S 238740-08-4/RN

L33 FILE 'CAPLUS' ENTERED AT 10:58:52 ON 05 APR 2004
1 S L32

L34 FILE 'CAPLUS' ENTERED AT 11:00:43 ON 05 APR 2004
1 S L6-L33

FILE 'REGISTRY' ENTERED AT 11:03:11 ON 05 APR 2004

FILE 'REGISTRY' ENTERED AT 11:03:50 ON 05 APR 2004

=>

US 2003108568 A1 20030612 US 2002-288340 20021104
PRAI US 1999-134406P P 19990517
US 1999-153406P P 19990910
US 1999-159783P P 19991015
EP 2000-932570 A3 20000517
WO 2000-IB763 W 20000517
WO 2000-US13576 W 20000517
US 2000-657332 A3 20000907
IT **152129-87-8 185805-61-2**
RL: PRP (Properties)
(unclaimed sequence; protection of endogenous therapeutic peptides from
peptidase activity through conjugation to blood components)

~~L3 ANSWER 5 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:790958 CAPLUS
DN 134:13569
TI Receptor-activity-modifying protein 1 forms heterodimers with two
G-protein-coupled receptors to define ligand recognition
AU Leuthauser, Kerstin; Gujer, Remo; Aldecoa, Amaya; McKinney, R. Anne; Muff,
Roman; Fischer, Jan A.; Born, Walter
CS Research Laboratory for Calcium Metabolism, Departments of Orthopaedic
Surgery and Medicine, Klinik Balgrist, University of Zurich, Zurich,
CH-8008, Switz.
SO Biochemical Journal (2000), 351(2), 347-351
CODEN: BIJOAK; ISSN: 0264-6021
PB Portland Press Ltd.
DT Journal
LA English
IT **155069-90-2**, Salmon calcitonin 8-32
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(receptor-activity-modifying protein 1 forms heterodimers with two
G-protein-coupled receptors to define ligand recognition)
RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3 ANSWER 6 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:719186 CAPLUS
DN 134:50939
TI Constitutive receptor systems for drug discovery
AU Chen, G.; Jayawickreme, C.; Way, J.; Armour, S.; Queen, K.; Watson, C.;
Ignar, D.; Chen, W.-J.; Kenakin, T.
CS Department of Receptor Biochemistry, Glaxo Wellcome Research and
Development, Research Triangle Park, NC, 27709, USA
SO Journal of Pharmacological and Toxicological Methods (1999), 42(4),
199-206
CODEN: JPTMEZ; ISSN: 1056-8719
PB Elsevier Science Inc.
DT Journal
LA English
IT **152129-87-8**, Ac 66 **189951-69-7**, Ac 512
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); BIOL (Biological study);
PROC (Process)
(constitutive receptor systems for drug discovery)
RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3 ANSWER 7 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:699213 CAPLUS
DN 133:267158
TI Preparation of pharmaceutical compositions containing calcium

metabolism-regulating peptides (calcitonin analogs)
 IN Orlowski, Ronald C.; Hanamura, Satoshi; Marumoto, Masahiko; Sakamoto, Kenji; Waki, Yoshihiro
 PA Tsumura & Co., Japan
 SO U.S., 52 pp., Cont.-in-part of U.S. Ser. No. 431,350, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6127519	A	20001003	US 1990-401432	19901221
	WO 9012809	A1	19901101	WO 1990-US2143	19900419
	W: AU, BR, CA, JP, KR, US, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
PRAI	US 1989-341800	B2	19890421		
	US 1989-437350	B2	19891116		
	WO 1990-US2143	W	19900419		
OS	MARPAT 133:267158				

IT **135437-27-3P**

RI: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pharmaceutical compns. containing calcium
 metabolism-regulating
 peptides (calcitonin analogs))

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:622458 CAPLUS
 DN 133:203412
 TI Methods for regulating gastrointestinal motility using amylin analogs
 IN Kolterman, Orville G.; Young, Andrew A.; Rink, Timothy J.; Brown, Kathleen Ann Keiting
 PA Amylin Pharmaceuticals, Inc., USA
 SO U.S., 50 pp., Cont.-in-part of U.S. Ser. No. 118,381, abandoned.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6114304	A	20000905	US 1994-302069	19940907
	CA 2171207	AA	19950316	CA 1994-2171207	19940907
	BR 9407424	A	19960409	BR 1994-7424	19940907
	EP 717635	A1	19960626	EP 1994-927398	19940907
	EP 717635	B1	20001115		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	HU 73490	A2	19960828	HU 1996-558	19940907
	CN 1134110	A	19961023	CN 1994-193931	19940907
	JP 09502443	T2	19970311	JP 1994-508823	19940907
	AT 197549	E	20001215	AT 1994-927398	19940907
	ES 2154299	T3	20010401	ES 1994-927398	19940907
	PT 717635	T	20010430	PT 1994-94927398	19940907
	RU 2177331	C2	20011227	RU 1996-107891	19940907
	SG 98356	A1	20030919	SG 1996-7979	19940907
	US 5795861	A	19980818	US 1995-471675	19950605
	NO 9600899	A	19960506	NO 1996-899	19960306
	US 6608029	B1	20030819	US 2000-576062	20000522
	GR 3035387	T3	20010531	GR 2001-400214	20010207
PRAI	US 1993-118381	B2	19930907		

US 1994-302069 A3 19940907
WO 1994-US10225 W 19940907

OS MARPAT 133:203412

IT **151804-77-2**, AC 0187

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(methods for regulating gastrointestinal motility using amylin analogs)

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3 ANSWER 9 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:488448 CAPLUS

DN 133:188071

TI Identification of key components in the irreversibility of salmon calcitonin binding to calcitonin receptors

AU Hilton, J. M.; Dowton, M.; Houssami, S.; Sexton, P. M.

CS Molecular Pharmacology Laboratory, Department of Pharmacology, The University of Melbourne, Parkville, 3052, Australia

SO Journal of Endocrinology (2000), 166(1), 213-226

~~CODEN: JOENAK; ISSN: 0022-0795~~

PB Society for Endocrinology

DT Journal

LA English

IT **155069-90-2**, 8-32-Calcitonin (salmon reduced) **189951-67-5**, SDZ-218-686 **189951-68-6**, SDZ-212-769 **189951-69-7**, AC 512

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(structural features and key components in the irreversibility of salmon calcitonin binding to calcitonin receptors)

RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3 ANSWER 10 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:17472 CAPLUS

DN 132:189251

TI Use of constitutive G protein-coupled receptor activity for drug discovery

AU Chen, Grace; Way, James; Armour, Susan; Watson, Chris; Queen, Ken; Jayawickreme, Channa K.; Chen, Wen-Ji; Kenakin, Terry

CS Departments of Receptor Biochemistry, Glaxo Wellcome Research and Development, Research Triangle Park, NC, USA

SO Molecular Pharmacology (2000), 57(1), 125-134

~~CODEN: MOPMA3; ISSN: 0026-895X~~

PB American Society for Pharmacology and Experimental Therapeutics

DT Journal

LA English

IT **152129-87-8** **189951-69-7**

RL: ANT (Analyte); ANST (Analytical study)

(constitutive G protein-coupled receptor activity for drug discovery)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3 ANSWER 11 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:810566 CAPLUS

DN 132:222841

TI Synthesis of salmon calcitonin analogs using Fmoc-based chemistry on MBHA resins

AU Yang, Bin; Ding, Zhen Kai; Han, Zong Jin; Zhang, Qi Kai

CS Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, Peop. Rep. China

SO Chinese Chemical Letters (1999), 10(7), 549-552

CODEN: CCLEE7; ISSN: 1001-8417

PB Chinese Chemical Society

DT Journal

LA English

IT 260998-90-1P

RL: SPN (Synthetic preparation); PREP (Preparation)

(synthesis of salmon calcitonin analogs using fluorenylmethoxycarbonyl on methylbenzhydrylamine resins)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ANSWER 12 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:529033 CAPLUS

DN 131:165322

TI Peptides with novel mixed amylin activities

IN Beeley, Nigel R. A.; Prickett, Kathryn S.; Beaumont, Kevin

PA Amylin Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9940928	A1	19990819	WO 1999-US2603	19990205
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2320962	AA	19990819	CA 1999-2320962	19990205
	EP 1053001	A1	20001122	EP 1999-906782	19990205
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002522355	T2	20020723	JP 2000-531179	19990205
	AU 766653	B2	20031023	AU 1999-26612	19990205
PRAI	US 1998-74746P	P	19980213		
	WO 1999-US2603	W	19990205		

OS MARPAT 131:165322

IT 238740-13-1P 238740-15-3P 238740-16-4P

238740-17-5P 238740-18-6P 238740-19-7P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PNU (Preparation, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(peptides with novel mixed amylin activities)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ANSWER 13 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1998:6054 CAPLUS

DN 128:123980

TI Expression cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells and their relationship to amylin receptors

AU Chen, Wen-Ji; Armour, Susan; Way, James; Chen, Grace; Watson, Chris; Irving, Paul; Cobb, Jeff; Kadwell, Sue; Beaumont, Kevin; Rimele, Tom; Kenakin, Terry

CS Department of Molecular Biology, Glaxo Wellcome, Research Triangle Park,

NC, 27709, USA
SO Molecular Pharmacology (1997), 52(6), 1164-1175
CODEN: MOPMA3; ISSN: 0026-895X
PB Williams & Wilkins
DT Journal
LA English
IT **152129-87-8, AC 66**

~~RL: BPR (Biological process);~~ BSU (Biological study, unclassified); BIOL
(Biological study); PROC (Process)
(expression cloning and receptor pharmacol. of human calcitonin
receptors from MCF-7 cells and relationship to amylin receptors)

* IT **189951-69-7P, AC512**
RL: BPR (Biological process); BSU (Biological study, unclassified); SPN
(Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC
(Process)
(expression cloning and receptor pharmacol. of human calcitonin
receptors from MCF-7 cells and relationship to amylin receptors)

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:565451 CAPLUS
DN 127:245020
TI Extracting Information from the Temperature Gradients of Polypeptide NH
Chemical Shifts. 1. The Importance of Conformational Averaging
AU Andersen, Niels H.; Neidigh, Jonathan W.; Harris, Scott M.; Lee, Gregory
M.; Liu, Zhihong; Tong, Hui
CS Chemistry Department Biophysics Program, University of Washington,
Seattle, WA, 98195, USA
SO Journal of the American Chemical Society (1997), 119(36), 8547-8561
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
IT **155069-90-2, 8-32-Calcitonin (salmon reduced)**
RL: PRP (Properties)
(extracting information from temperature gradients of polypeptide NH
chemical shifts
and importance of conformational averaging)

L3 ~~ANSWER 15 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:272955 CAPLUS
DN 126:338955
TI Structure/function relationships of calcitonin analogs as agonists,
antagonists, or inverse agonists in a constitutively activated receptor
cell system
AU Pozvek, Gordana; Hilton, Joanne M.; Quiza, Maribel; Houssami, Souheir;
Sexton, Patrick M.
CS Neurobiology Unit, St. Vincent's Institute of Medical Research, Victoria,
3065, Australia
SO Molecular Pharmacology (1997), 51(4), 658-665
CODEN: MOPMA3; ISSN: 0026-895X
PB Williams & Wilkins
DT Journal
LA English
IT **155069-90-2, Salmon calcitonin-(8-32) 189951-67-5, SDZ**
218-686 **189951-68-6, SDZ 212-769 189951-69-7, AC 512**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(structure/function relationships of calcitonin analogs as agonists,
antagonists, or inverse agonists in a constitutively activated receptor
cell system)

RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ANSWER 16 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:754438 CAPLUS
DN 126:104425
TI Amylin antagonist peptides as antidiabetics
IN Albrecht, Elisabeth; Jones, Howard; Gaeta, Laura S. L.; Prickett, Kathryn
S.; Beaumont, Kevin
PA Amylin Pharmaceuticals, Inc., USA
SO U.S., 74 pp., Cont.-in-part of U.S. Ser. No. 744,586, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5580953	A	19961203	US 1991-794288	19911119
	WO 9310147	A1	19930527	WO 1992-US10011	19921119
	W:	AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD			
	RW:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG			
	AU 9331431	A1	19930615	AU 1993-31431	19921119
	AU 672589	B2	19961010		
	HU 64976	A2	19940328	HU 1993-2062	19921119
	JP 06504795	T2	19940602	JP 1992-509532	19921119
	NO 9302604	A	19930917	NO 1993-2604	19930719
PRAI	US 1991-744586	B2	19910814		
	US 1991-794288	A	19911119		
	WO 1992-US10011	A	19921119		

OS MARPAT 126:104425

IT ~~152129-87-8P~~ 185805-48-5P 185805-61-2P

185806-22-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amylin antagonist peptides as antidiabetics)

~~L3~~ ANSWER 17 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:729048 CAPLUS
DN 126:8719
TI Preparation of cyclopeptides as calcitonin analogs
IN Shibata, Kenji; Yamasaki, Motoo; Hamada, Masako; Tamaoki, Tatsuya; Kosaka, Nobuo; Sato, Soichiro
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9629343	A1	19960926	WO 1996-JP666	19960315
	W:	CA, JP, US			
	RW:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	CA 2190633	AA	19960926	CA 1996-2190633	19960315
	EP 770623	A1	19970502	EP 1996-906038	19960315
	R:	AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE			
	US 5977298	A	19991102	US 1997-934741	19970922
PRAI	JP 1995-61026	A	19950320		

WO 1996-JP666 W 19960315

OS MARPAT 126:8719

IT **155069-90-2P**, 8-32-Calcitonin (salmon reduced)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclopeptides as calcitonin analogs for bone absorption inhibitors)

L3 ~~ANSWER 18 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:696025 CAPLUS

DN 126:26933

TI Design of receptor selective peptides that antagonize the actions of amylin in vivo

AU Prickett, K. S.; Albrecht, E.; Soares, C. J.; Lumpkin, R. H.; Gaeta, L. S. L.; Moore, C. X.; Young, A. A.; Beeley, N. R. A.; Beaumont, K.

CS Amylin Pharmaceuticals, Inc., San Diego, CA, 92121, USA

SO Peptides: Chemistry, Structure and Biology, Proceedings of the American Peptide Symposium, 14th, Columbus, Ohio, June 18-23, 1995 (1996), Meeting Date 1995, 620-622. Editor(s): Kaumaya, Pravin T. P.; Hodges, Robert S. Publisher: Mayflower Scientific, Kingswinford, UK.
CODEN: 63NTAF

DT Conference

LA English

IT **144500-19-6P** ~~151804-77-2P~~ ~~155069-90-2P~~,

8-32-Calcitonin (salmon reduced)

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design of receptor selective peptides that antagonize actions of amylin in vivo)

L3 ~~ANSWER 19 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:616676 CAPLUS

DN 126:3243

TI Cold denaturation of monomeric peptide helixes

AU Andersen, Niels H.; Cort, John R.; Liu, Zhinhong; Sjoberg, Sandra J.; Tong, Hui

CS Chemistry Department, University of Washington, Seattle, WA, 98195, USA

SO Journal of the American Chemical Society (1996), 118(42), 10309-10310
CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

IT **155069-90-2**, 8-32-Calcitonin (salmon reduced)

RL: PEP (Physical, engineering or chemical process); PRP (Properties); PROC (Process)

(VLGKLSQELHKLQTPRTNTGSGTPNH₂; cold denaturation of monomeric peptide helixes)

L3 ~~ANSWER 20 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:77611 CAPLUS

DN 124:136179

TI Effect of (8-32) salmon calcitonin, an amylin antagonist, on insulin, glucagon and somatostatin release: study in the perfused pancreas of the rat

AU Silvestre, R. A.; Salas, M.; Rodriguez-Gallardo, J.; Garcia-Hermida, O.; Fontela, T.; Marco, J.

CS Clinica Puerta Hierro, Universidad Autonoma Madrid, Madrid, Spain

SO British Journal of Pharmacology (1996), 117(2), 347-50
CODEN: BJPCBM; ISSN: 0007-1188

PB Stockton

DT Journal
LA English
IT **155069-90-2**, Salmon calcitonin-(8-32)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(salmon calcitonin-(8-32) effect on insulin, glucagon and somatostatin release in pancreas)

~~L3~~ ~~ANSWER 21 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1995:11657 CAPLUS
DN 122:81967
TI Synthesis of [4,5-3H-Leu4]salmon calcitonin
AU Birtle, T.; White, A. J.; Woodhouse, D. P.
CS Cambridge Res. Biochem., Zeneca Spec., Billingham/Cleveland, TS23 1YN, UK
SO Journal of Labelled Compounds and Radiopharmaceuticals (1994), 34(4), 401-10
CODEN: JLCRD4; ISSN: 0362-4803
DT Journal
LA English
IT **160275-15-0DP**, Pepsyn KAm-bound
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate in synthesis of tritium-labeled leucine calcitonin)

~~L3~~ ~~ANSWER 22 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:596867 CAPLUS
DN 121:196867
TI MCF-7 cell binding site assays for amylin agonists and antagonists
IN Beaumont, Kevin; Moore, Candace X.
PA Amylin Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 50 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9418571	A1	19940818	WO 1994-US2004	19940214
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9462495	A1	19940829	AU 1994-62495	19940214
PRAI	US 1993-16618		19930212		
	WO 1994-US2004		19940214		

IT **152129-87-8**
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(MCF-7 cell binding site assays for amylin agonists and antagonists)

L3 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:596503 CAPLUS
DN 121:196503
TI The presence of islet amyloid polypeptide/calcitonin gene-related peptide/salmon calcitonin binding sites in the rat nucleus accumbens
AU Veale, Philippa R.; Bhogal, Ranjev; Morgan, David G. A.; Smith, David M.; Bloom, Stephen R.
CS Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK
SO European Journal of Pharmacology (1994), 262(1-2), 133-41
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal

LA English
IT **155069-90-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(islet amyloid polypeptide and calcitonin binding by nucleus accumbens and brain stem response to)

~~L3 ANSWER 24 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:290832 CAPLUS
DN 120:290832
TI Methods for treating renin-related disorders with amylin antagonists
IN Young, Andrew A.; Rink, Timothy J.
PA Amylin Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9405317	A1	19940317	WO 1993-US8221	19930901
	W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, LU, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5376638	A	19941227	US 1992-939106	19920901
	AU 9350991	A1	19940329	AU 1993-50991	19930901
	EP 661991	A1	19950712	EP 1993-920445	19930901
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08501296	T2	19960213	JP 1994-507409	19930901
PRAI	US 1992-939106	A2	19920901		
	WO 1993-US8221	W	19930901		

IT **155069-90-2**

RL: BIOL (Biological study)
(as amylin antagonist, amylin-induced plasma renin activity in rat prevention with)

IT **151804-77-2**

RL: BIOL (Biological study)
(as amylin antagonist, for treatment of renin-related disorders)

~~L3 ANSWER 25 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:46708 CAPLUS
DN 120:46708
TI Myotonin receptors for screening myotonin receptor binding compounds
IN Beaumont, Kevin
PA Amylin Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9314408	A1	19930722	WO 1993-US310	19930114
	W: CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 582693	A1	19940216	EP 1993-903473	19930114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 06506777	T2	19940728	JP 1993-512649	19930114
PRAI	US 1992-821739		19920114		
	WO 1993-US310		19930114		

IT **152129-87-8**

RL: ANST (Analytical study)
(calcitonin binding to myotonin receptor of rat skeletal muscle
inhibition by)

L3-----ANSWER 26 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1994:31230 CAPLUS

DN 120:31230

TI Preparation of novel amylin antagonist peptides and uses thereof

IN Gaeta, Laura S. L.; Jones, Howard; Albrecht, Elisabeth; Prickett, Kathryn;
Beaumont, Kevin

PA Amylin Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9310147	A1	19930527	WO 1992-US10011	19921119
	W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
	<u>US 5580953</u>	A	19961203	US 1991-794288	19911119
	AU 9331431	A1	19930615	AU 1993-31431	19921119
	AU 672589	B2	19961010		
	JP 06504795	T2	19940602	JP 1992-509532	19921119
	NO 9302604	A	19930917	NO 1993-2604	19930719
PRAI	US 1991-794288	A	19911119		
	US 1991-744586	B2	19910814		
	WO 1992-US10011	A	19921119		
IT	144500-19-6P 151804-59-0P 151804-77-2P 155069-90-2P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of, as amylin antagonist)				

L3-----ANSWER 27 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1992:626460 CAPLUS

DN 117:226460

TI N-terminal truncation of salmon calcitonin leads to calcitonin antagonists

AU Feyen, Jean H. M.; Cardinaux, Francis; Gamse, Rainer; Bruns, Christian;
Azria, Moise; Trechsel, Ulrich

CS Preclin. Res., SANDOZ PHARMA Ltd., Basel, CH-4002, Switz.

SO Biochemical and Biophysical Research Communications (1992), 187(1), 8-13

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

IT 110917-40-3 110917-52-7 144500-18-5

~~144500-19-6~~ 144522-74-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(biol. activity of, structure in relation to)

L3-----ANSWER 28 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:499269 CAPLUS

DN 115:99269

TI Preparation of pharmaceutical compositions containing calcium
metabolism-regulating peptides (calcitonin analogs)

IN Orłowski, Ronald C.; Hanamura, Satoshi; Marumoto, Masahiko; Sakamoto,
Kenji; Waki, Yoshihiro

PA Tsumura and Co., Japan

SO PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9012809	A1	19901101	WO 1990-US2143	19900419
	W: AU, BR, CA, JP, KR, US, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2030795	AA	19901022	CA 1990-2030795	19900419
	CA 2030795	C	19991130		
	AU 9055487	A1	19901116	AU 1990-55487	19900419
	AU 640141	B2	19930819		
	EP 423326	A1	19910424	EP 1990-908015	19900419
	EP 423326	B1	19980826		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	BR 9006746	A	19910806	BR 1990-6746	19900419
	JP 03505589	T2	19911205	JP 1990-506839	19900419
	JP 2778249	B2	19980723		
	AT 170191	E	19980915	AT 1990-908015	19900419
	ES 2119746	T3	19981016	ES 1990-908015	19900419
	KR 141973	B1	19980615	KR 1990-702657	19901220
	US 6127519	A	20001003	US 1990-401432	19901221
PRAI	US 1989-341800	A2	19890421		
	US 1989-437350	A2	19891116		
	WO 1990-US2143	A	19900419		
OS	MARPAT 115:99269				
IT	135437-27-3P				

RL: PREP (Preparation)
(calcitonin synthetic analog, preparation of, for calcium
metabolism-regulating
pharmaceutical)

L3-ANSWER-29-OF-37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1991:214432 CAPLUS

DN 114:214432

TI Therapeutic aerosol spray formulations comprising drug complexes with
extenders

IN Felt, George Robert; Warchol, Mark Peter

PA Rorer International (Overseas), Inc., USA

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9009781	A1	19900907	WO 1990-US928	19900221
	W: AU, BR, CA, FI, JP, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
	CA 2050905	AA	19900824	CA 1990-2050905	19900221
	AU 9051949	A1	19900926	AU 1990-51949	19900221
	EP 460064	A1	19911211	EP 1990-904101	19900221
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	JP 05508616	T2	19931202	JP 1990-504385	19900221
	NO 9103298	A	19911022	NO 1991-3298	19910822
PRAI	US 1989-314605		19890223		
	WO 1990-US928		19900221		
OS	MARPAT 114:214432				
IT	108470-28-6D, complexes with extenders				
	RL: PROC (Process)				
	(aerosol formulation of)				

L3 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1991:12192 CAPLUS
 DN 114:12192
 TI Intranasal calcitonin formulations
 IN Klunk, Lewis J., Jr.; Grebow, Peter E.; Li, Herschel H.
 PA Rorer International (Overseas), Inc., USA
 SO Eur. Pat. Appl., 22 pp.

CODEN: EPXXDW

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 358234	A2	19900314	EP 1989-116685	19890908
	EP 358234	A3	19901031		
	EP 358234	B1	19930407		
	R: DE, ES, FR, GB, IT				
	US 5026825	A	19910625	US 1988-242000	19880908
	JP 02115130	A2	19900427	JP 1989-231803	19890908
	ES 2061851	T3	19941216	ES 1989-116685	19890908
PRAI	US 1988-242000		19880908		
OS	MARPAT 114:12192				
IT	108470-29-7 130914-84-0				
	RL: BIOL (Biological study)				
	(intranasal composition of, aminolevulinate as stabilizer in)				

L3 ~~ANSWER 31 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1990:217544 CAPLUS
 DN 112:217544
 TI Preparation of calcitonin and LH-RH antagonist peptides modified by sugar molecules or polyhydroxy compounds
 IN Albert, Rainer; Bauer, Wilfried; Cardinaux, Francois; Pless, Janos
 PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.; Sandoz A.-G.
 SO PCT Int. Appl., 82 pp.

CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8909786	A1	19891019	WO 1989-EP373	19890407
	W: AT, AU, CH, DE, JP, KR				
	DK 8901636	A	19891030	DK 1989-1636	19890405
	GB 2218102	A1	19891108	GB 1989-7652	19890405
	GB 2218102	B2	19920916		
	FR 2629825	A1	19891013	FR 1989-4661	19890406
	FR 2629825	B1	19930514		
	BE 1004357	A4	19921110	BE 1989-389	19890406
	NL 8900864	A	19891101	NL 1989-864	19890407
	AU 8933628	A1	19891103	AU 1989-33628	19890407
	JP 01305099	A2	19891208	JP 1989-89566	19890407
	SE 8901241	A	19900202	SE 1989-1241	19890407
	DE 3990350	T	19900426	DE 1989-3990350	19890407
	ES 2015645	A6	19900901	ES 1989-1228	19890407
	ZA 8902570	A	19901228	ZA 1989-2570	19890407
	CH 682152	A	19930730	CH 1989-4362	19890407
	IL 89881	A1	19940530	IL 1989-89881	19890407
	AT 8909006	A	19970115	AT 1989-9006	19890407
	AU 8932637	A1	19891012	AU 1989-32637	19890410
	AU 623385	B2	19920514		
	GB 2246782	A1	19920212	GB 1991-18452	19910829

GB 2246782 B2 19920916
 FR 2682680 A1 19930423 FR 1992-11637 19920928
 JP 07089994 A2 19950404 JP 1994-116257 19940530
 US 5541159 A 19960730 US 1994-346118 19941129
 PRAI GB 1988-8275 19880408
 GB 1988-8528 19880412
 GB 1989-7652 19890405
 US 1989-334969 19890407
 WO 1989-EP373 19890407
 US 1991-781789 19911023
 US 1992-916284 19920717
 US 1993-57066 19930503
 OS MARPAT 112:217544
 IT **110917-25-4P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and reaction of, in preparation of hypocalcemic and LHRH
 antagonist)
 IT **127010-49-5P 127010-51-9P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as hypocalcemic and LHRH antagonist)

L3 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:213349 CAPLUS
 DN 110:213349
 TI Preparation of glycosylated bioactive peptide drugs with prolonged
 duration of action
 PA Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H., Austria; Sandoz A.-G.;
 Sandoz-Patent-G.m.b.H.
 SO PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8802756	A2	19880421	WO 1987-EP593	19871012
	WO 8802756	A3	19880714		
	W: AT, CH, DE				
	NL 8702345	A	19880502	NL 1987-2345	19871001
	NL 194729	B	20020902		
	NL 194729	C	20030107		
	HU 46710	A2	19881128	HU 1987-4432	19871001
	HU 206890	B	19930128		
	HU 210192	B	19950228	HU 1990-6340	19871001
	FR 2609991	A1	19880729	FR 1987-13949	19871007
	FR 2609991	B1	19950310		
	GB 2199829	A1	19880720	GB 1987-23737	19871009
	GB 2199829	B2	19910417		
	BE 1003752	A4	19920609	BE 1987-1187	19871009
	AU 8779564	A1	19880414	AU 1987-79564	19871012
	AU 617986	B2	19911212		
	DK 8705327	A	19880414	DK 1987-5327	19871012
	DK 174337	B1	20021216		
	FI 8704495	A	19880414	FI 1987-4495	19871012
	SE 8703938	A	19880414	SE 1987-3938	19871012
	JP 63101399	A2	19880506	JP 1987-257047	19871012
	JP 06045639	B4	19940615		
	DE 3790635	T	19881006	DE 1987-3790635	19871012
	CH 677233	A	19910430	CH 1988-2210	19871012
	PL 154068	B1	19910628	PL 1987-281585	19871012
	PL 156156	B1	19920529	PL 1987-268173	19871012

PL 157648	B1	19920630	PL 1987-285052	19871012
CH 680512	A	19920915	CH 1990-3804	19871012
CH 682632	A	19931029	CH 1989-1353	19871012
IL 102184	A1	19940530	IL 1987-102184	19871012
ES 2007418	A6	19890616	ES 1987-2913	19871013
ZA 8707688	A	19890628	ZA 1987-7688	19871013
GB 2199831	A1	19880720	GB 1988-537	19880112
GB 2199831	B2	19910417		
FR 2619566	A1	19890224	FR 1988-2759	19880304
FR 2619566	B1	19931210		
RO 101204	B1	19920110	RO 1988-134904	19880815
DD 298932	A5	19920319	DD 1988-318954	19880815
SK 278318	B6	19961002	SK 1988-5618	19880815
CZ 281518	B6	19961016	CZ 1988-5618	19880815
SU 1792418	A3	19930130	SU 1988-4356419	19880816
ZA 8902413	A	19890628	ZA 1989-2413	19890331
GB 2233652	A1	19910116	GB 1990-11637	19900524
GB 2233652	B2	19910821		
JP 03014599	A2	19910123	JP 1990-147161	19900604
JP 2744910	B2	19980428		
AT 9100794	A	19991215	AT 1991-794	19910416
AT 406680	B	20000725		
AU 9180150	A1	19911031	AU 1991-80150	19910703
AU 634664	B2	19930225		
SE 518630	C2	20021105	SE 1993-1172	19930407
US 5656721	A	19970812	US 1994-272704	19940707
FI 9500960	A	19950301	FI 1995-960	19950301
FI 99113	B	19970630		
FI 99113	C	19971010		
PRAI DE 1986-3634797	A	19861013		
DE 1986-3634825	A	19861013		
DE 1986-3634826	A	19861013		
DE 1987-3712626	A	19870414		
CH 1987-3153	A	19870817		
HU 1987-4432	A	19871001		
GB 1987-23737	A3	19871009		
CH 1988-2210	A	19871012		
FI 1987-4495	A	19871012		
IL 1987-84150	A3	19871012		
WO 1987-EP593	W	19871012		
US 1987-108188	B1	19871013		
AT 1987-9028	A	19880609		
US 1991-782021	B1	19911024		
US 1993-138567	B3	19931018		
OS MARPAT 110:213349				
IT 111056-98-5P				
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT				
(Reactant or reagent)				
(preparation and acylation of, by quinic acid)				
IT 119643-70-8P 119643-71-9P 119643-72-0P				
119643-73-1P 119643-74-2P 119643-75-3P				
119662-42-9P 119662-43-0P 119683-34-0P				
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological				
study); PREP (Preparation); USES (Uses)				
(preparation of, as drug)				
IT 110917-78-7P 119643-11-7P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as drug intermediate)				
IT 119683-15-7				
RL: RCT (Reactant); RACT (Reactant or reagent)				
(reaction of, in preparation of drug)				

L3 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:598934 CAPLUS
 DN 107:198934
 TI Preparation of calcitonin analogs for treatment of osteoporosis and hypocalcemia
 IN Cardinaux, Francois; Pless, Janos; Buck, Robert Helmut
 PA Sandoz-Patent-G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 13 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3640042	A1	19870611	DE 1986-3640042	19861124
	NL 8602950	A	19870701	NL 1986-2950	19861120
	HU 44794	A2	19880428	HU 1986-4812	19861120
	CH 671229	A	19890815	CH 1986-4717	19861125
	DK 8605801	A	19870605	DK 1986-5801	19861202
	GB 2184729	A1	19870701	GB 1986-28739	19861202
	GB 2184729	B2	19900725		
	BE 905849	A1	19870603	BE 1986-11581	19861203
	FR 2590902	A1	19870605	FR 1986-16885	19861203
	FR 2590902	B1	19941223		
	FI 8604939	A	19870605	FI 1986-4939	19861203
	SE 8605189	A	19870605	SE 1986-5189	19861203
	AU 8666061	A1	19870611	AU 1986-66061	19861203
	AU 600242	B2	19900809		
	JP 62132898	A2	19870616	JP 1986-288629	19861203
	JP 08005916	B4	19960124		
	US 4758550	A	19880719	US 1986-937580	19861203
	ES 2012510	A6	19900401	ES 1986-3267	19861203
	ZA 8609182	A	19880727	ZA 1986-9182	19861204
PRAI	DE 1985-3542859		19851204		
	DE 1986-3614784		19860502		

IT **110734-10-6P 110917-67-4P 110917-71-0P
 110917-78-7P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and deprotection of, in synthesis of calcitonin analog)

IT **110917-69-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and peptide coupling of, in synthesis of calcitonin analog)

IT **110917-25-4P 110917-26-5P 110917-27-6P
 110917-30-1P 110917-36-7P 110917-39-0P
 110917-40-3P 110917-41-4P 110917-42-5P
 110917-43-6P 110917-44-7P 110917-45-8P
 110917-46-9P 110917-47-0P 110917-48-1P
 110917-49-2P 110917-50-5P 110917-51-6P
 110917-52-7P 110917-53-8P 110917-54-9P
 110917-55-0P 110917-56-1P 110917-57-2P
 110917-58-3P 110917-59-4P 110917-60-7P
 110917-62-9P 110945-70-5P 110945-74-9P
 111056-98-5P**

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of, as calcitonin analog for treatment of osteoporosis and hypocalcemia)

L3 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1987:407614 CAPLUS
 DN 107:7614

TI Des-2-serine, 3 asparagine-calcitonin
IN Orlowski, Ronald C.; Seyler, Jay K.
PA Armour Pharmaceutical Co., USA
SO U.S., 10 pp.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4622388	A	19861111	US 1985-797074	19851112
PRAI	US 1985-797074		19851112		

IT **108470-28-6P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclization of)

IT **108569-11-5DP**, benzydrylamine resin-bound

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and deprotection and resin cleavage of)

IT **108470-29-7P 108470-30-0P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for removal of calcium from blood)

L3 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1987:67675 CAPLUS

DN 106:67675

TI 1a-Endo-glycine-calcitonin

IN Seyler, Jay K.; Stahl, Glenn L.; Orlowski, Ronald C.

PA Armour Pharmaceutical Co., USA

SO U.S., 10 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4497732	A	19850205	US 1983-544183	19831021
PRAI	US 1983-544183		19831021		

IT **106494-04-6DP**, benzhydrylamine resin-bound

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and solid-phase peptide coupling of)

L3 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1986:609401 CAPLUS

DN 105:209401

TI Des-4-leucine-calcitonin

IN Orlowski, Ronald C.; Seyler, Jay K.; Stahl, Glenn L.

PA Armour Pharmaceutical Co., USA

SO U.S., 11 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4605514	A	19860812	US 1984-653748	19840924
PRAI	US 1984-653748		19840924		

IT **105217-26-3P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for reduction of serum calcium concentration)

L3 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1981:66084 CAPLUS
DN 94:66084
TI Cyclization of peptides
IN Hughes, John L.; Liu, Robert C.; Seyler, Jay K.
PA Armour Pharmaceutical Co., USA
SO U.S., 21 pp.
CODEN: USXXAM

DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 4212795	A	19800715	US 1978-960229	19781113
PRAI	US 1978-960229		19781113		
IT	76404-63-2DP , benzhydrylamine resin-bound RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and partial deblocking of)				

=>

~~L3~~ ~~ANSWER 1 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:552077 CAPLUS
 DN 139:271279
 TI Human amylin actions on rat cholinergic basal forebrain neurons:
 Antagonism of beta-amyloid effects
 AU Jhamandas, Jack H.; Harris, Kim H.; Cho, Caroline; Fu, Wen; MacTavish,
 David
 CS Department of Medicine (Neurology) and Centre for Alzheimer and
 Neurodegenerative Research, University of Alberta, Edmonton, AB, T6G 2S2,
 Can.
 SO Journal of Neurophysiology (2003), 89(6), 2923-2930
 CODEN: JONEA4; ISSN: 0022-3077
 PB American Physiological Society
 DT Journal
 LA English
 IT **151804-77-2**, AC 0187
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (amylin receptor blockade by AC 187 attenuates effects of amylin and
 amyloid β protein on rat diagonal band of Broca neuron)
 RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ~~ANSWER 2 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:83851 CAPLUS
 DN 138:379679
 TI Novel calcitonin-(8-32)-sensitive adrenomedullin receptors derived from
 co-expression of calcitonin receptor with receptor activity-modifying
 proteins
 AU Kuwasako, Kenji; Kitamura, Kazuo; Nagoshi, Yasuko; Eto, Tanenao
 CS First Department of Internal Medicine, Miyazaki Medical College, Kiyotake,
 Miyazaki, 889-1692, Japan
 SO Biochemical and Biophysical Research Communications (2003), 301(2),
 460-464
 CODEN: BBRCA9; ISSN: 0006-291X
 PB Elsevier Science
 DT Journal
 LA English
 IT **155069-90-2**, Salmon calcitonin(8-32)
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (characterization of calcitonin-(8-32)-sensitive adrenomedullin
 receptors derived from co-expression of calcitonin receptor with RAMP)
 RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ~~ANSWER 3 OF 37~~ CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:560084 CAPLUS
 DN 135:153114
 TI Preparation of peptide antagonists of CGRP-receptor superfamily
 IN Smith, Derek David; Saha, Shankar; Abel, Peter W.
 PA Creighton University, USA
 SO U.S., 24 pp.
 CODEN: USXXAM
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6268474	B1	20010731	US 1998-70504	19980430
	US 2002068814	A1	20020606	US 2001-813345	20010320
PRAI	US 1998-70504	A3	19980430		

OS MARPAT 135:153114

IT 185805-61-2

RL: PRP (Properties)

(unclaimed sequence; preparation of peptide antagonists of CGRP-receptor superfamily)

RE.CNT 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

~~L3~~ ANSWER 4 OF 37 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2000:824291 CAPLUS

DN 134:21425

TI Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

IN Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen

PA Conjuchem, Inc., Can.

SO PCT Int. Appl., 733 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000069900	A2	20001123	WO 2000-US13576	20000517
	WO 2000069900	A3	20010215		
	WO 2000069900	C2	20020704		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	WO 2000070665	A2	20001123	WO 2000-IB763	20000517
	WO 2000070665	A3	20010419		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP	1105409	A2	20010613	EP 2000-936023	20000517
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP	1171582	A2	20020116	EP 2000-929748	20000517
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP	1264840	A1	20021211	EP 2002-14617	20000517
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP	2003500341	T2	20030107	JP 2000-619018	20000517
JP	2003508350	T2	20030304	JP 2000-618316	20000517
AU	765753	B2	20030925	AU 2000-51393	20000517
US	6514500	B1	20030204	US 2000-657332	20000907
ZA	2001006676	A	20020719	ZA 2001-6676	20010814
ZA	2001009110	A	20020613	ZA 2001-9110	20011105
US	2003108567	A1	20030612	US 2002-287892	20021104

L2 ANSWER 1 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 260998-90-1 REGISTRY

SEQ3 1 Val-Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-
=====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 7-30

L2 ANSWER 2 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-19-7 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 3 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-18-6 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 4 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-17-5 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 5 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-16-4 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Arg-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 6 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-15-3 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ser-Val-Leu-Gly-Arg-Leu-Ser-
====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 7 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 238740-13-1 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Arg-Leu-Ser-
====
11 Gln-Glu-Leu-His-Arg-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 8 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 189951-69-7 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Arg-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 2-25

L2 ANSWER 9 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 189951-68-6 REGISTRY

SEQ3 1 Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-
====
11 His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-
====
21 Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 3-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 10 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 189951-67-5 REGISTRY

SEQ3 1 Asn-Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-
====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 7-30

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 11 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 185806-22-8 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 12 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 185805-61-2 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 13 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 185805-48-5 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Gly-Thr-Pro
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 14 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 160275-15-0 REGISTRY

SEQ3 1 Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

~~L2 ANSWER 15 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN~~
RN 155069-90-2 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Gly-Thr-Pro
====

HITS AT: 2-25

DIS
RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 16 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 152129-87-8 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Gly-Thr-Pro
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

X
L2 ANSWER 17 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 151804-77-2 REGISTRY

DIS
SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 18 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 151804-59-0 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====
21 Gly-Ser-Asn-Thr-Tyr
====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 19 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 144522-74-7 REGISTRY

SEQ3 1 Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-
====
11 His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-
====
21 Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 3-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

DIS
L2 ANSWER 20 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 144500-19-6 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
====
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
====

21 Gly-Ser-Gly-Thr-Pro
=====
21 Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 21 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 144500-18-5 REGISTRY

SEQ3 1 Asn-Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-
=====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 7-30

RELATED SEQUENCES AVAILABLE WITH SEQLINK

NO L2 ANSWER 22 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 135437-27-3 REGISTRY

SEQ3 1 Asn-Leu-Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-
=====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 7-30

L2 ANSWER 23 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 130914-84-0 REGISTRY

SEQ3 1 Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-
=====
11 His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-
=====
21 Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 3-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 24 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 127010-51-9 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
=====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
=====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 25 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 127010-49-5 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
=====

11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 26 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119683-34-0 REGISTRY

SEQ3 1 Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
===
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 27 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119683-15-7 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
===
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 28 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119662-43-0 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
===
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
===
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
===
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
===
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: === === === === === === ===
5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 29 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119662-42-9 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
 === === === === ===
 11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
 === === === === ===
 21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 30 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-75-3 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 31 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-74-2 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 32 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-73-1 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 33 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-72-0 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 34 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-71-9 REGISTRY

SEQ3 1 Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-Ser-Gln-

11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 35 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-70-8 REGISTRY

SEQ3 1 Ser-Thr-Lys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 36 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 119643-11-7 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 37 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 111056-98-5 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 38 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110945-74-9 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 39 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110945-70-5 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

SEQ3 1 Cys

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 40 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-78-7 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 41 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-71-0 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
====

11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 6-29

SEQ3 1 Cys

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
===
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 6-29

SEQ3 1 Cys

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
===
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 6-29

SEQ3 1 Cys

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 42 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-70-9 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
===
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 6-29

SEQ3 1 Cys

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 43 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-69-6 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
===
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 44 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-68-5 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 45 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-67-4 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
=====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 46 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-66-3 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 47 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-62-9 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Aib-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

L2 ANSWER 48 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-60-7 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 49 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-59-4 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 50 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-58-3 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Gly-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: === === === === === === === ===
6-29

L2 ANSWER 51 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-57-2 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
 === === === === ===
 11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
 === === === === ===
 21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 52 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-56-1 REGISTRY

SEQ3 1 Glp-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

L2 ANSWER 53 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-55-0 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
 === === === === ===
 11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
 === === === === ===
 21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 54 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-54-9 REGISTRY

SEQ3 1 Pro-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

L2 ANSWER 55 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-53-8 REGISTRY

SEQ3 1 Ala-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
 === === === === ===
 11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
 === === === === ===
 21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
 === === === === ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 56 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-52-7 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 57 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-51-6 REGISTRY

SEQ3 1 Ala-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 58 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-50-5 REGISTRY

SEQ3 1 Leu-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

L2 ANSWER 59 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-49-2 REGISTRY

SEQ3 1 Leu-Ala-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 60 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-48-1 REGISTRY

SEQ3 1 Phe-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

L2 ANSWER 61 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-47-0 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 62 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-46-9 REGISTRY

SEQ3 1 Leu-Ala-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 63 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-45-8 REGISTRY

SEQ3 1 Ser-Leu-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

SEQ3 1 Cys

L2 ANSWER 64 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-44-7 REGISTRY

SEQ3 1 Ser-Asn-Leu-Thr-Cys-Val-Leu-Gly-Lys-Leu-
====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 7-30

SEQ3 1 Cys

L2 ANSWER 65 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-43-6 REGISTRY

SEQ3 1 Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

SEQ3 1 Cys

L2 ANSWER 66 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-42-5 REGISTRY

SEQ3 1 Ser-Asn-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 7-30

SEQ3 1 Cys

L2 ANSWER 67 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-41-4 REGISTRY

SEQ3 1 Leu-Ser-Thr-Phe-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

L2 ANSWER 68 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-40-3 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 69 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-39-0 REGISTRY

SEQ3 1 Leu-Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-
====
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
====
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 70 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-36-7 REGISTRY

SEQ3 1 Ser-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

====
HITS AT: 7-30

SEQ3 1 Cys

L2 ANSWER 71 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-30-1 REGISTRY

SEQ3 1 Asn-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
====
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
====
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 7-30

SEQ3 1 Cys

L2 ANSWER 72 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-27-6 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 73 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-26-5 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 74 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110917-25-4 REGISTRY

SEQ3 1 Ser-Thr-Ala-Val-Leu-Gly-Lys-Leu-Ser-Gln-
====
11 Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-
====
21 Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
====

HITS AT: 5-28

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 75 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 110734-10-6 REGISTRY

SEQ3 1 Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-Ser-
====

11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=== ===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=== ===

HITS AT: 6-29

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 76 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 108569-11-5 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
=== ===
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=== ===
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=== ===

HITS AT: 7-30

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 77 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 108470-30-0 REGISTRY

SEQ3 1 Leu-Ser-Thr-Asu-Val-Leu-Gly-Lys-Leu-Ser-
=== ===
11 Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-Pro-
=== ===
21 Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=== ===

HITS AT: 6-29

L2 ANSWER 78 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 108470-29-7 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
=== ===
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=== ===
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=== ===

HITS AT: 7-30

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 79 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 108470-28-6 REGISTRY

SEQ3 1 Cys-Leu-Ser-Thr-Cys-Val-Leu-Gly-Lys-Leu-
=== ===
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
=== ===
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro
=== ===

HITS AT: 7-30

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 80 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 106494-04-6 REGISTRY

SEQ3 1 Cys-Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-

11 His-Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-
21 Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 3-26

RELATED SEQUENCES AVAILABLE WITH SEQLINK

L2 ANSWER 81 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 105217-26-3 REGISTRY

SEQ3 1 Ser-Asn-Ser-Thr-Asu-Val-Leu-Gly-Lys-Leu-
11 Ser-Gln-Glu-Leu-His-Lys-Leu-Gln-Thr-Tyr-
21 Pro-Arg-Thr-Asn-Thr-Gly-Ser-Gly-Thr-Pro

HITS AT: 7-30

L2 ANSWER 82 OF 82 REGISTRY COPYRIGHT 2004 ACS on STN
RN 76404-63-2 REGISTRY

SEQ3 1 Val-Leu-Gly-Lys-Leu-Ser-Gln-Glu-Leu-His-
11 Lys-Leu-Gln-Thr-Tyr-Pro-Arg-Thr-Asn-Thr-
21 Gly-Ser-Gly-Thr-Pro

HITS AT: 2-25

RELATED SEQUENCES AVAILABLE WITH SEQLINK

=>